Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial

Autor: Zuur, L., Vos, J. L., Elbers, J. B., Krijgsman, O., Qiao, X., van der Leun, A., Smit, L., van den Brekel, M. W., Tan, B., Jasperse, B., Vogel, W. V., Willems, S. M., Al-Mamgani, A., Peeper, D., Schumacher, T. N., Blank, C. U., de Boer, J. P., Haanen, J. B. A. G.

Publikováno v: Annals of Oncology, 31(Suppl. 4). Oxford University Press

Background Nivolumab (NIVO) alone or with ipilimumab (COMBO) immune checkpoint blockade (ICB) prior to curative surgery has shown promising results in multiple tumor types. We completed a phase Ib/II study with neoadjuvant NIVO or COMBO in resectable

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::8a641c5cad31ee758ededdae4de3e579
https://research.rug.nl/en/publications/afc5f669-a26a-461b-ad4b-ad4d09df09d4

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Personalized neck irradiation guided by sentinel lymph node biopsy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx with a clinically negative neck: (Chemo)radiotherapy to the PRIMary tumor only. Protocol of the PRIMO study.

Autor: van den Bosch S; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Takes RP; Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands., de Ridder M; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., de Bree R; Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Al-Mamgani A; Department of Radiation Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Schreuder WH; Department of Head and Neck Surgical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Hoebers FJP; Department of Radiation Oncology (Maastro), Maastricht University Medical Center+, GROW-School for Oncology and Reproduction, Maastricht, The Netherlands., van Weert S; Department of Otorhinolaryngology and Head and Neck Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands., Elbers JBW; Department of Radiation Oncology, Erasmus MC Cancer Centre, Rotterdam, The Netherlands., Hardillo JA; Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Centre, Rotterdam, The Netherlands., Meijer TWH; Department of Radiation Oncology, University Medical Center Groningen, Groningen, The Netherlands., Plaat BEC; Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Groningen, Groningen, The Netherlands., de Jong MA; Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands., Jansen JC; Department of Otorhinolaryngology and Head and Neck Surgery, Leiden University Medical Center, Leiden, The Netherlands., Wellenstein DJ; Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands., van den Broek GB; Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands., Vogel WV; Department of Medical Imaging/Department of Nuclear Medicine, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Arens AIJ; Department of Medical Imaging/Department of Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Kaanders JHAM; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.

Publikováno v: Clinical and translational radiation oncology [Clin Transl Radiat Oncol] 2023 Oct 26; Vol. 44, pp. 100696. Date of Electronic Publication: 2023 Oct 26 (Print Publication: 2024).